On Today’s Calendar: nothing More Calendars: U.S. Earnings | Conf. Calls | Surprises | IPO | Economic Potential swing trades: See one of the recent ‘Chart Reading‘ posts for some potential swing candidates. Also be sure to check my typical swing trade entry & exit rules. Potential day trades: (From Briefing.com) Gapping Down In reaction to disappointing earnings/guidance:...
Results 1 - 10 of 169 for "BIO"
This is how I feel right now. Waiting for the antibiotics to take effect. Light posting until the swelling and throbbing subside.A guy with a toothache goes to see his dentist. After examining the tooth, the dentist tells the patient he is going to have to give him an injection for the pain. The patient says, "No way! I don't want an injection." The dentist replies, "OK, I'll give you gas." "No...
Don't confuse HOLDRs with exchange-traded funds.
Filed under: Deals, Good news, Newsletters, Johnson and Johnson (JNJ), Stocks to BuyOver the long holiday weekend, I had a chance to do some much needed reading. Given my vocation, sometimes I like to read articles that have little to do with the markets or finance as a way of recharging my batteries. Of course, even when I partake in this guilty pleasure, there really is no way to truly escape...
Will historic returns give way to additional gains? A preview of this week's earnings & economic data Reports on both construction spending & manufacturing disappoint "It's no time for the Fed to act like a bashful virgin." -Vincent Reinhart Governments' ability to pay for rescues in doubt Bailout spending is out of control Let's just throw a lot more money at the problem From a market economy ...
Filed under: Deals, Johnson and Johnson (JNJ)Johnson & Johnson (NYSE: JNJ) offered to acquire breast implant maker Mentor Corp (NYSE: MNT). At $31 per share, J&J's tender offer for Mentor is a 92% premium to its closing price last Friday. J&J plans to run the $373 million Mentor as a stand-alone business under its Ethicon division, reasoning that the skills of its 1,300 employees wi...
Filed under: International markets, Newsletters, Stocks to Buy"Investors should keep a defensive posture," says Richard Moroney. However, the editor of the blue chip advisory service, Dow Theory Forecasts, see opportunity in two drug stocks that he has just added to his buy list. "In general, we prefer to let the market's action signal that the point of maximum pessimism has passed before deplo...
Jon Friedman's Media Web: Rupert Murdoch, explained by Newser's Michael Wolff
Sun, Nov 30, 11:58 PM ET
Rupert Murdoch, chief executive officer of News Corp., is one of the most successful and complex leaders in the media universe. But his biographer Michael Wolff has a simple explanation for what makes Murdoch tick.
LONDON (Reuters) - The prospects of Swiss drugmaker Roche raising a $45 billion syndicated loan to finance the buyout of the rest of U.S. biotech group Genentech are becoming increasingly remote.
Black Friday, the traditional start of the holiday shopping season, sees a 1% gain in online shopping from last year, even as broader seasonal sales are trending down, according to ComScore.